DOXIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Doxil, and what generic alternatives are available?
Doxil is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.
The generic ingredient in DOXIL is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Doxil
A generic version of DOXIL was approved as doxorubicin hydrochloride by PFIZER on December 23rd, 1987.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DOXIL?
- What are the global sales for DOXIL?
- What is Average Wholesale Price for DOXIL?
Summary for DOXIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for DOXIL |
| What excipients (inactive ingredients) are in DOXIL? | DOXIL excipients list |
| DailyMed Link: | DOXIL at DailyMed |
US Patents and Regulatory Information for DOXIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-001 | Nov 17, 1995 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-002 | Jun 13, 2000 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
